LONDON (ShareCast) - (Sharecast News) - ValiRx told investors on Thursday that its clinical-stage therapeutics had continued to demonstrate "significant potential" for addressing unmet medical needs in oncology.
The AIM-listed biotech received confirmation earlier this week that principal investigators had approved and signed a clinical study report on VAL 401, the group's oral treatment of late-stage non-small cell lung adenocarcinoma.

ValiRx revealed it was in detailed discussions regarding a pivotal phase three clinical trial on the drug, with first dosing expected to take place next year.

In other developments, the VAL 201 phase one/two clinical trial for patients affected by hormone-sensitive and hormone-resistant prostate cancer has shown the compound was consistently high in safety and tolerability, with signs of efficacy throughout its clinical study.

Chief executive Dr Satu Vainikka said: "Since the pharmaceutical industry is increasingly looking for novel new therapies in the oncology arena, I believe we are in a new and very exciting phase."

As of 0900 BST, ValiRx shares had slumped 6.68% to 2.33p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE